These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 23532732)

  • 21. EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities.
    Quadros MR; Connelly S; Kari C; Abrams MT; Wickstrom E; Rodeck U
    Cancer Biol Ther; 2006 May; 5(5):498-504. PubMed ID: 16582597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma.
    Richter-Larrea JA; Robles EF; Fresquet V; Beltran E; Rullan AJ; Agirre X; Calasanz MJ; Panizo C; Richter JA; Hernandez JM; Roman-Gomez J; Prosper F; Martinez-Climent JA
    Blood; 2010 Oct; 116(14):2531-42. PubMed ID: 20570860
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma.
    Kong LR; Chua KN; Sim WJ; Ng HC; Bi C; Ho J; Nga ME; Pang YH; Ong WR; Soo RA; Huynh H; Chng WJ; Thiery JP; Goh BC
    Mol Cancer Ther; 2015 Jul; 14(7):1750-60. PubMed ID: 25939760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
    Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
    Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Romidepsin and Azacitidine Synergize in their Epigenetic Modulatory Effects to Induce Apoptosis in CTCL.
    Rozati S; Cheng PF; Widmer DS; Fujii K; Levesque MP; Dummer R
    Clin Cancer Res; 2016 Apr; 22(8):2020-31. PubMed ID: 26660520
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.
    Mazzio EA; Soliman KFA
    Cancer Genomics Proteomics; 2018; 15(5):349-364. PubMed ID: 30194076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.
    San José-Eneriz E; Agirre X; Jiménez-Velasco A; Cordeu L; Martín V; Arqueros V; Gárate L; Fresquet V; Cervantes F; Martínez-Climent JA; Heiniger A; Torres A; Prósper F; Roman-Gomez J
    Eur J Cancer; 2009 Jul; 45(10):1877-89. PubMed ID: 19403302
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Oncogenic kit triggers Shp2/Erk1/2 pathway to down-regulate the pro-apoptotic protein Bim and to promote apoptosis resistance in leukemic cells.
    Selimoglu-Buet D; Gallais I; Denis N; Guillouf C; Moreau-Gachelin F
    PLoS One; 2012; 7(11):e49052. PubMed ID: 23145067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.
    Ramakrishnan VG; Miller KC; Macon EP; Kimlinger TK; Haug J; Kumar S; Gonsalves WI; Rajkumar SV; Kumar SK
    Haematologica; 2019 Oct; 104(10):2061-2074. PubMed ID: 30846494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
    Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
    Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytotoxicity of farnesyltransferase inhibitors in lymphoid cells mediated by MAPK pathway inhibition and Bim up-regulation.
    Ding H; Hackbarth J; Schneider PA; Peterson KL; Meng XW; Dai H; Witzig TE; Kaufmann SH
    Blood; 2011 Nov; 118(18):4872-81. PubMed ID: 21673341
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.
    Cortes JR; Patrone CC; Quinn SA; Gu Y; Sanchez-Martin M; Mackey A; Cooke AJ; Shih BB; Laurent AP; Trager MH; Ferrando AA; Geskin LJ; Palomero T
    J Invest Dermatol; 2021 Dec; 141(12):2908-2920.e7. PubMed ID: 34089720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
    Li H; Zhou S; Li X; Wang D; Wang Y; Zhou C; Schmid-Bindert G
    Cancer Biother Radiopharm; 2013 Mar; 28(2):115-23. PubMed ID: 23270470
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adenovirus 5 E1A enhances histone deacetylase inhibitors-induced apoptosis through Egr-1-mediated Bim upregulation.
    Yamaguchi H; Chen CT; Chou CK; Pal A; Bornmann W; Hortobagyi GN; Hung MC
    Oncogene; 2010 Oct; 29(41):5619-29. PubMed ID: 20676141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
    Kim M; Thompson LA; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells.
    Abutin RM; Chen J; Lung TK; Lloyd JA; Sawyer ST; Harada H
    Exp Hematol; 2009 Feb; 37(2):151-8. PubMed ID: 19100675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
    Hall CP; Reynolds CP; Kang MH
    Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical Studies Support Combined Inhibition of BET Family Proteins and Histone Deacetylases as Epigenetic Therapy for Cutaneous T-Cell Lymphoma.
    Zhao L; Okhovat JP; Hong EK; Kim YH; Wood GS
    Neoplasia; 2019 Jan; 21(1):82-92. PubMed ID: 30529073
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reactive Oxygen Species-Mediated Synergism of Fenretinide and Romidepsin in Preclinical Models of T-cell Lymphoid Malignancies.
    Makena MR; Koneru B; Nguyen TH; Kang MH; Reynolds CP
    Mol Cancer Ther; 2017 Apr; 16(4):649-661. PubMed ID: 28119491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
    Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
    Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.